BACKGROUND: Synthesis of clinical effectiveness from multiple trials is a well-established component of decision-making. Time-to-event outcomes are often synthesised using the Cox proportional hazards model assuming a constant hazard ratio over time. However, with an increasing proportion of trials reporting treatment effects where hazard ratios vary over time and with differing lengths of follow-up across trials, alternative synthesis methods are needed. OBJECTIVES: To compare and contrast five modelling approaches for synthesis of time-to-event outcomes and provide guidance on key considerations for choosing between the modelling approaches. METHODS: The Cox proportional hazards model and five other methods of estimating treatment effects...
Objectives: To develop efficient approaches for fitting network meta-analysis (NMA) models with t...
Background: Model structure, despite being a key source of uncertainty in economic evaluations, is o...
Model-based meta-analysis (MBMA) is increasingly used in drug development to inform decision making ...
Background Synthesis of clinical effectiveness from multiple trials is a well-established component ...
Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate and rank ...
Objectives: Network meta-analysis (NMA) methods extend the standard pair-wise framework to allow sim...
Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate and rank...
THESIS TITLE: SYNTHESIS OF CLUSTERED TIME-TO-EVENT OUTCOMES Background: Previous studies have propos...
Network meta‐analysis (NMA) combines direct and indirect evidence from trials to calculate and rank ...
Aim: Technical Support Document 21 discusses trial-based, flexible relative survival models. The aut...
Background: Model-based meta-analysis (MBMA) is increasingly used to inform drug-development decisio...
<div><p>Background</p><p>Randomized Controlled Trials almost invariably utilize the hazard ratio cal...
AbstractBackgroundCost-effectiveness analysis often requires information on the effectiveness of int...
The main focus of this Phd project is the application of Bayesian models in Biostatistics.It has bec...
International audienceBackground: The difference in restricted mean survival time (rmstD(t*)), the a...
Objectives: To develop efficient approaches for fitting network meta-analysis (NMA) models with t...
Background: Model structure, despite being a key source of uncertainty in economic evaluations, is o...
Model-based meta-analysis (MBMA) is increasingly used in drug development to inform decision making ...
Background Synthesis of clinical effectiveness from multiple trials is a well-established component ...
Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate and rank ...
Objectives: Network meta-analysis (NMA) methods extend the standard pair-wise framework to allow sim...
Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate and rank...
THESIS TITLE: SYNTHESIS OF CLUSTERED TIME-TO-EVENT OUTCOMES Background: Previous studies have propos...
Network meta‐analysis (NMA) combines direct and indirect evidence from trials to calculate and rank ...
Aim: Technical Support Document 21 discusses trial-based, flexible relative survival models. The aut...
Background: Model-based meta-analysis (MBMA) is increasingly used to inform drug-development decisio...
<div><p>Background</p><p>Randomized Controlled Trials almost invariably utilize the hazard ratio cal...
AbstractBackgroundCost-effectiveness analysis often requires information on the effectiveness of int...
The main focus of this Phd project is the application of Bayesian models in Biostatistics.It has bec...
International audienceBackground: The difference in restricted mean survival time (rmstD(t*)), the a...
Objectives: To develop efficient approaches for fitting network meta-analysis (NMA) models with t...
Background: Model structure, despite being a key source of uncertainty in economic evaluations, is o...
Model-based meta-analysis (MBMA) is increasingly used in drug development to inform decision making ...